Prospective Safety Monitoring of Haemophilus influenzae Type b and Heptavalent Pneumococcal Conjugate Vaccines in Kagoshima, Japan

DOI Web Site PubMed 被引用文献1件 参考文献5件
  • Nishi Junichiro
    Department of Microbiology, Kagoshima University Graduate School of Medical and Dental Sciences
  • Tokuda Koichi
    Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences
  • Imuta Naoko
    Department of Microbiology, Kagoshima University Graduate School of Medical and Dental Sciences
  • Minami Taketsugu
    Minami Clinic
  • Kawano Yoshifumi
    Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences

書誌事項

タイトル別名
  • Prospective Safety Monitoring of <i>Haemophilus influenzae</i> Type b and Heptavalent Pneumococcal Conjugate Vaccines in Kagoshima, Japan

この論文をさがす

抄録

Haemophilus influenzae type b (Hib) conjugate vaccine (PRP-T) and heptavalent pneumococcal conjugate vaccine (PCV7) were introduced in Japan in December 2008 and February 2010, respectively. The concurrent administration of these vaccines is routinely performed worldwide. However, the safety of the simultaneous administration of these vaccines has not been fully evaluated in Japan, because it has rarely been performed thus far. We conducted a 2-year prospective, observational, multicenter study on PRP-T and PCV7 safety from February 2009 through January 2011 in 29 facilities located in Kagoshima Prefecture, Japan. Objective severe adverse events included anaphylactoid reaction, encephalitis/encephalopathy, neurological events, severe focal reactions, systemic eruption/urticaria, fever above 39℃ within 2 days after inoculation, and other complications requiring hospitalization. The incidences of these events for PRP-T and PCV7 administration were 0.68% (76/11,197) and 0.92% (28/3,049), respectively. No deaths or subsequent complications were reported during the course of the study. There was no significant difference in the incidence of severe adverse events between the single and co-administration groups for both vaccines: PRP-T, 0.55% (31/5,662) versus 0.81% (45/5,535; P = 0.11); PCV7, 0.88% (11/1,247) versus 0.94% (17/1,802; P = 0.86). These results suggest that the simultaneous administration of vaccines including PRP-T and/or PCV7 does not increase the incidence of severe adverse events in Japanese children.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (5)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ